BRAF and melanoma: In this respect, detailed genomic analysis of melanomas with acquired resistance to inhibition of both BRAF and MEK demonstrated amplification of the changes detected in tumors resistant to single-agent therapy as well as more-frequent combinations of genetic alterations that affect both MAPK and PI3K pathways (Moriceau et al., 2015).